This article was originally published in The Gray Sheet
Executive SummaryExpects to begin clinical trials of an in vitro blood test designed to measure the effectiveness of cancer treatment "in the first half of 1993," according to a recent press release. The test measures the level of human carcinoma antigen (HCA) in the bloodstream. A U.S. patent application was filed in February for the test and two other products: an in vivo imaging agent designed to identify a tumor site with a radioactive label and a cancer vaccine which "uses proprietary anti-idiotypic monoclonal antibodies to act like purified HCA and activate an immune system response to treat malignant tumors." Epigen plans to file an investigational new drug application for the imaging agent in the second quarter.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.